Great Novel Therapeutics Biotech & Medicals (7427.TWO)
- Previous Close
38.15 - Open
38.15 - Bid 36.05 x --
- Ask 36.95 x --
- Day's Range
35.50 - 38.15 - 52 Week Range
30.30 - 55.20 - Volume
64,384 - Avg. Volume
174,031 - Market Cap (intraday)
1.613B - Beta (5Y Monthly) -0.00
- PE Ratio (TTM)
-- - EPS (TTM)
-2.55 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Great Novel Therapeutics Biotech & Medicals engages in the development of drugs for the treatment of advanced and refractory cancers. It develops drugs for cancer immunotherapy, including tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was formerly known as GNT Biotech & Medicals Corporation. Great Novel Therapeutics Biotech & Medicals was founded in 2013 and is based in Taipei City, Taiwan.
www.gntbm.com.twRecent News: 7427.TWO
View MorePerformance Overview: 7427.TWO
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 7427.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 7427.TWO
View MoreValuation Measures
Market Cap
1.67B
Enterprise Value
1.09B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
933.24
Price/Book (mrq)
2.63
Enterprise Value/Revenue
648.50
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.51%
Return on Equity (ttm)
-17.97%
Revenue (ttm)
1.69M
Net Income Avi to Common (ttm)
-104.92M
Diluted EPS (ttm)
-2.55
Balance Sheet and Cash Flow
Total Cash (mrq)
582.76M
Total Debt/Equity (mrq)
1.63%
Levered Free Cash Flow (ttm)
-53.21M